Matheus Negri Boschiero1,2, Camila Vantini Capasso Palamim1,2, Fernando Augusto Lima Marson1,2. 1. Laboratory of Cell and Molecular Tumor Biology and Bioactive Compounds, São Francisco University, Bragança Paulista, SP, Brazil. 2. Laboratory of Human and Medical Genetics, São Francisco University, Bragança Paulista, SP, Brazil.
Abstract
INTRODUCTION: Brazil is one of the epicenters of COVID-19 pandemic and faces several hindrances to make his COVID-19 vaccination plan efficient. METHODS: The Brazilian COVID-19 vaccination plan was evaluated and the hindrances to make the COVID-19 vaccination plan efficient were described and discussed. RESULTS: High territorial extension might contribute to a delay on the COVID-19 vaccination, due to difficulty in delivering vaccines to furthest Brazilian states and to all the interior cities. The choice among the vaccines should be done based on the type of storage and must consider the transport conditions necessary to maintain its effectiveness. The indigenous individuals were included with health-care workers as the first group to be vaccinated, inflaming the number of vaccines doses distributed in states where the indigenous population have higher prevalence. The antivaccine movement and the politicization of the vaccine are also hindrances to be overcome in Brazil. The COVID-19 incidence or mortality rate and the distribution of intensive care units (ICUs) are not a criterion to distribute the vaccines, as we did not identify a correlation between these markers and the number of vaccines. However, a strong or very strong correlation occurred between the number of COVID-19 vaccines and the number of COVID-19 cases, deaths by COVID-19, gross domestic product, as well as populational density. A total of 83,280,475 doses of COVID-19 vaccines were distributed in Brazil. In the first dose, the Coronavac (Sinovac™), AZD1222 (AstraZeneca/Oxford™), and BNT162b (Pfizer/BioNTech™) vaccines were responsible to vaccinate, respectively, 9.61%, 6.69%, and 0.35% of the Brazilian population. In the second dose, the Coronavac, AZD1222, and BNT162b vaccines were responsible to vaccinate, respectively, 7.52%, 0.53%, and <0.01% of the Brazilian population. CONCLUSIONS: The Federal Government must evaluate the hindrances and propose solutions to maximize the immunization against COVID-19 on Brazil.
INTRODUCTION: Brazil is one of the epicenters of COVID-19 pandemic and faces several hindrances to make his COVID-19 vaccination plan efficient. METHODS: The Brazilian COVID-19 vaccination plan was evaluated and the hindrances to make the COVID-19 vaccination plan efficient were described and discussed. RESULTS: High territorial extension might contribute to a delay on the COVID-19 vaccination, due to difficulty in delivering vaccines to furthest Brazilian states and to all the interior cities. The choice among the vaccines should be done based on the type of storage and must consider the transport conditions necessary to maintain its effectiveness. The indigenous individuals were included with health-care workers as the first group to be vaccinated, inflaming the number of vaccines doses distributed in states where the indigenous population have higher prevalence. The antivaccine movement and the politicization of the vaccine are also hindrances to be overcome in Brazil. The COVID-19 incidence or mortality rate and the distribution of intensive care units (ICUs) are not a criterion to distribute the vaccines, as we did not identify a correlation between these markers and the number of vaccines. However, a strong or very strong correlation occurred between the number of COVID-19 vaccines and the number of COVID-19 cases, deaths by COVID-19, gross domestic product, as well as populational density. A total of 83,280,475 doses of COVID-19 vaccines were distributed in Brazil. In the first dose, the Coronavac (Sinovac™), AZD1222 (AstraZeneca/Oxford™), and BNT162b (Pfizer/BioNTech™) vaccines were responsible to vaccinate, respectively, 9.61%, 6.69%, and 0.35% of the Brazilian population. In the second dose, the Coronavac, AZD1222, and BNT162b vaccines were responsible to vaccinate, respectively, 7.52%, 0.53%, and <0.01% of the Brazilian population. CONCLUSIONS: The Federal Government must evaluate the hindrances and propose solutions to maximize the immunization against COVID-19 on Brazil.
Entities:
Keywords:
COVID-19; SARS-CoV-2; immunization; public health; vaccine; viral infection
Authors: Mariana Vercesi de Albuquerque; Ana Luiza d'Ávila Viana; Luciana Dias de Lima; Maria Paula Ferreira; Edgard Rodrigues Fusaro; Fabíola Lana Iozzi Journal: Cien Saude Colet Date: 2017-04
Authors: Nelma Nunes da Silva; Veronica Batista Cambraia Favacho; Gabriella de Andrade Boska; Emerson da Costa Andrade; Neuri Pires das Merces; Márcia Aparecida Ferreira de Oliveira Journal: Rev Bras Enferm Date: 2020-06-01
Authors: Lindsey R Baden; Hana M El Sahly; Brandon Essink; Karen Kotloff; Sharon Frey; Rick Novak; David Diemert; Stephen A Spector; Nadine Rouphael; C Buddy Creech; John McGettigan; Shishir Khetan; Nathan Segall; Joel Solis; Adam Brosz; Carlos Fierro; Howard Schwartz; Kathleen Neuzil; Larry Corey; Peter Gilbert; Holly Janes; Dean Follmann; Mary Marovich; John Mascola; Laura Polakowski; Julie Ledgerwood; Barney S Graham; Hamilton Bennett; Rolando Pajon; Conor Knightly; Brett Leav; Weiping Deng; Honghong Zhou; Shu Han; Melanie Ivarsson; Jacqueline Miller; Tal Zaks Journal: N Engl J Med Date: 2020-12-30 Impact factor: 91.245
Authors: Camila Vantini Capasso Palamim; Manoela Marques Ortega; Fernando Augusto Lima Marson Journal: J Racial Ethn Health Disparities Date: 2020-10-06
Authors: Nathália M S Sansone; Matheus N Boschiero; Manoela M Ortega; Isadora A Ribeiro; Andressa O Peixoto; Roberto T Mendes; Fernando A L Marson Journal: Lancet Reg Health Am Date: 2022-01-07
Authors: Nathália Mariana Santos Sansone; Matheus Negri Boschiero; Fernando Augusto Lima Marson Journal: Front Microbiol Date: 2022-07-01 Impact factor: 6.064